ELISA/assay

Mouse Isocitrate Dehydrogenase 1, Soluble ELISA Kit

MBS094288

48-Strip-Wells

470 USD

ELISA Kit

Mouse Isocitrate Dehydrogenase 1, Soluble ELISA Kit

[Isocitrate Dehydrogenase 1, Soluble]

[isocitrate dehydrogenase 1 (NADP+), soluble, isoform CRA_b; Isocitrate dehydrogenase [NADP] cytoplasmic; isocitrate dehydrogenase [NADP] cytoplasmic; isocitrate dehydrogenase [NADP] cytoplasmic; NADP(+)-specific ICDH; oxalosuccinate decarboxylase; epididymis luminal protein 216; epididymis secretory protein Li 26; NADP-dependent isocitrate dehydrogenase, cytosolic; NADP-dependent isocitrate dehydrogenase, peroxisomal; isocitrate dehydrogenase 1 (NADP+), soluble; Cytosolic NADP-isocitrate dehydrogenase; IDP; NADP(+)-specific ICDH; Oxalosuccinate decarboxylase]

[IDH1]

[IDH1; IDH1; IDH; IDP; IDCD; IDPC; PICD; HEL-216; HEL-S-26; PICD; IDH]

IDHC_HUMAN

Mouse

286

No significant cross-reactivity or interference between this analyte and analogues is observed.

Store all reagents at 2-8 degree C

Samples: Body fluids, tissue homogenates, secretions or feces samples. Assay Type: Quantitative Sandwich. Detection Range: 3.12 ng/ml - 100 ng/ml. Sensitivity: 1.0 ng/ml.

Intra-assay Precision: Intra-assay CV (%) is less than 15%. Inter-assay Precision: Inter-assay CV (%) is less than 15%. [CV(%) = SD/mean ×100].

Background/Introduction: This Quantitative Sandwich ELISA kit is only for in vitro research use only, not for drug, household, therapeutic or diagnostic applications! This kit is intended to be used for determination the level of IDH1 (hereafter termed "analyte") in undiluted original Mouse body fluids, tissue homogenates, secretions or feces samples. This kit is NOT suitable for assaying non-biological sources of substances.

119590846

EAW70440.1

O75874

46,659 Da

2-Oxocarboxylic Acid Metabolism Pathway (714485); 2-Oxocarboxylic Acid Metabolism Pathway (717400); Abnormal Conversion Of 2-oxoglutarate To 2-hydroxyglutarate Pathway (771598); Biosynthesis Of Amino Acids Pathway (790012); Biosynthesis Of Amino Acids Pathway (795174); Carbon Metabolism Pathway (814926); Carbon Metabolism Pathway (817567); Citrate Cycle (TCA Cycle) Pathway (82927); Citrate Cycle (TCA Cycle) Pathway (288); Citrate Cycle (TCA Cycle, Krebs Cycle) Pathway (855811)

Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases have been reported: three NAD(+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP(+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. Each NADP(+)-dependent isozyme is a homodimer. The protein encoded by this gene is the NADP(+)-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes. It contains the PTS-1 peroxisomal targeting signal sequence. The presence of this enzyme in peroxisomes suggests roles in the regeneration of NADPH for intraperoxisomal reductions, such as the conversion of 2, 4-dienoyl-CoAs to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume 2-oxoglutarate, namely the alpha-hydroxylation of phytanic acid. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production. Alternatively spliced transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Sep 2013]

IDH1: an oxidoreductase that catalyzes the third step of the TCA cycle: the oxidative decarboxylation of isocitrate, consuming NADP(+), and producing alpha-ketoglutarate (alpha-KG) and CO2. Alpha-KG is an activator the dioxygenases that hydroxylate the transcription factor HIF and lead to its degradation by VHL. Since HIF turns on oncogenic pathways, IDH1 has apparent tumor suppressor activity. Homo-dimerization is required for activity. Each subunit binds 1 magnesium or manganese ion. IDH1 is located in the cytosol and peroxisomes. Somatic mutations affecting arginine 132 (R132) are found in 80% of grade II?III gliomas and secondary glioblastomas in humans, and cause disease in a tissue-specific fashion. Only a single copy of the gene has been found to be mutated in tumours. Mutations of R132 to H, C, S, G, V, or L have been reported to be neomorphic, abolishing the conversion of isocitrate to alpha-KG. Instead, alpha-KG is converted to R(-)-2-hydroxyglutarate (2HG). Elevated levels of 2HG correlate with an elevated risk of malignant brain tumors. Neomorphic mutations in IDH1 and IDH2 convert alpha-KG to 2-hydroxyglutarate (2-HG) occur in a high percentage of patients with cytogenetically normal acute myeloid leukemia (AML). Protein type: EC 1.1.1.42; Oxidoreductase; Carbohydrate Metabolism - citrate (TCA) cycle; Other Amino Acids Metabolism - glutathione. Chromosomal Location of Human Ortholog: 2q33.3. Cellular Component: peroxisomal matrix; mitochondrion; cytoplasm; peroxisome; cytosol. Molecular Function: protein homodimerization activity; magnesium ion binding; isocitrate dehydrogenase (NADP+) activity; NADP binding; NAD binding; receptor binding. Biological Process: isocitrate metabolic process; NADPH regeneration; glyoxylate cycle; glutathione metabolic process; response to steroid hormone stimulus; tricarboxylic acid cycle; response to oxidative stress; cellular lipid metabolic process; female gonad development; 2-oxoglutarate metabolic process. Disease: Glioma Susceptibility 1

48-Strip-Wells

470 USD

96-Strip-Wells

680

5x96-Strip-Wells

3100

10x96-Strip-Wells

6095